We are live on
!
Find out more
RCM
RA Capital Management Portfolio holdings
AUM
$9.44B
1-Year Est. Return
157.3%
This Fund
S&P 500
This Quarter
Est. Return
+87.55%
1 Year Est. Return
+157.3%
3 Year Est. Return
+589.39%
5 Year Est. Return
+654.96%
10 Year Est. Return
+50,915.53%
AUM
$5.13B
AUM Growth
+$1.97B
(+62%)
Cap. Flow
+$788M
Cap. Flow
% of AUM
15.36%
Top 10 Holdings %
Top 10 Hldgs %
55.31%
Holding
66
New
18
Increased
9
Reduced
12
Closed
9
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
FMTX
Forma Therapeutics Holdings, Inc. Common Stock
FMTX
|
+$391M |
| 2 |
Novavax
NVAX
|
+$182M |
| 3 |
Vaxcyte
PCVX
|
+$177M |
| 4 |
Legend Biotech
LEGN
|
+$97M |
| 5 |
MacroGenics
MGNX
|
+$79.6M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
RARX
Ra Pharmaceuticals, Inc. Common Stock
RARX
|
+$233M |
| 2 |
Exelixis
EXEL
|
+$77.9M |
| 3 |
ZGNX
Zogenix, Inc.
ZGNX
|
+$44.1M |
| 4 |
Gilead Sciences
GILD
|
+$41M |
| 5 |
Relmada Therapeutics
RLMD
|
+$22.3M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 93.1% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
26
Geron
GERN
$828M
| $65.7M | 1.28% |
+30,126,299
| New | +$45M |
|
|
ETNB
27
DELISTED
89bio
ETNB
| $63M | 1.23% |
3,161,214
| – | – |
|
|
AKUS
28
DELISTED
Akouos Inc
AKUS
| $51.3M | 1% |
+2,281,249
| New | +$50.8M |
|
|
TRIL
29
DELISTED
Trillium Therapeutics Inc.
TRIL
| $49.9M | 0.97% |
6,162,694
-198,752
| -3% | -$1.23M |
|
|
ORTX
30
DELISTED
Orchard Therapeutics plc American Depositary Shares
ORTX
| $45.7M | 0.89% |
1,040,319
+3,853
| +0.4% | +$353K |
|
31
Ardelyx
ARDX
$1.22B
| $43.3M | 0.84% |
6,260,904
-155,780
| -2% | -$1.08M |
|
32
Crinetics Pharmaceuticals
CRNX
$8.84B
| $40.8M | 0.8% |
2,328,698
+367,489
| +19% | +$6.26M |
|
|
33
Relmada Therapeutics
RLMD
$557M
| $38.1M | 0.74% |
851,907
-528,081
| -38% | -$22.3M |
|
|
PRVL
34
DELISTED
Prevail Therapeutics Inc. Common Stock
PRVL
| $37.2M | 0.72% |
2,494,691
-745,843
| -23% | -$11.5M |
|
35
Arcutis Biotherapeutics
ARQT
$3.36B
| $35.2M | 0.69% |
1,165,184
| – | – |
|
36
Stoke Therapeutics
STOK
$1.8B
| $26.7M | 0.52% |
1,119,963
| – | – |
|
|
SCPH
37
DELISTED
scPharmaceuticals
SCPH
| $25.9M | 0.5% |
3,518,998
| – | – |
|
|
AVDL
38
DELISTED
Avadel Pharmaceuticals
AVDL
| $25.3M | 0.49% |
+3,126,131
| New | +$27.6M |
|
39
Enliven Therapeutics
ELVN
$3.92B
| $22.9M | 0.45% |
207,337
-156,250
| -43% | -$17.5M |
|
40
Ocular Therapeutix
OCUL
$1.79B
| $22.7M | 0.44% |
+2,727,272
| New | +$18.1M |
|
41
Larimar Therapeutics
LRMR
$397M
| $19.5M | 0.38% |
+1,515,151
| New | +$17.6M |
|
|
CNCE
42
DELISTED
Concert Pharmaceuticals, Inc.
CNCE
| $18.5M | 0.36% |
1,858,474
| – | – |
|
43
Verastem
VSTM
$510M
| $15.7M | 0.31% |
760,771
-789,617
| -51% | -$20.9M |
|
44
Syndax Pharmaceuticals
SNDX
$1.69B
| $15.2M | 0.3% |
+1,023,067
| New | +$15.6M |
|
45
Celldex Therapeutics
CLDX
$2.99B
| $14.9M | 0.29% |
+1,150,000
| New | +$5.1M |
|
46
Sutro Biopharma
STRO
$401M
| $14.9M | 0.29% |
+191,964
| New | +$18.4M |
|
47
Solid Biosciences
SLDB
$794M
| $13.4M | 0.26% |
304,744
| – | – |
|
|
RPTX
48
DELISTED
Repare Therapeutics
RPTX
| $12.7M | 0.25% |
+409,000
| New | +$13.1M |
|
|
LYRA
49
DELISTED
LYRA THERAPEUTICS INC
LYRA
| $9.25M | 0.18% |
+16,317
| New | +$11.9M |
|
50
Passage Bio
PASG
$14.4M
| $8.82M | 0.17% |
16,132
| – | – |
|
Similar funds
RCMNY
SCM
SIM
NPT
AC
PVI
WPL
BAMF
RA Capital Management's Q2 2020 Portfolio in Review
As of Q2 2020, RA Capital Management held 66 positions worth $5.13B, up 62% from $3.17B the previous quarter. Its ten largest holdings account for 55% of the portfolio.
RA Capital Management deployed $788M of net new capital in Q2 2020, opening 18 new positions and adding to 9 existing holdings. Its largest new stake was Forma Therapeutics Holdings, Inc. Common Stock: 9,011,651 shares worth $419M.
By sector, the portfolio is most concentrated in Healthcare at 93% of assets, down from 93% a quarter earlier.
On the sell side, the largest reduction was Zogenix, Inc., an estimated $44.1M trimmed.
- RA Capital Management's largest Q2 2020 buy was Forma Therapeutics Holdings, Inc. Common Stock: 9,011,651 shares worth $419M.
- RA Capital Management added most to TG Therapeutics in Q2 2020, an estimated $38.7M increase.
- RA Capital Management's biggest Q2 2020 reduction was Zogenix, Inc., cutting an estimated $44.1M.
- RA Capital Management fully exited Ra Pharmaceuticals, Inc. Common Stock in Q2 2020, selling an estimated $233M.
- RA Capital Management's ten largest holdings make up 55% of its $5.13B portfolio in Q2 2020.
- RA Capital Management opened 18 new positions and closed 9 in Q2 2020.
- RA Capital Management's portfolio value rose 62% quarter-over-quarter to $5.13B.
Based on RA Capital Management's 13F filing for Q2 2020, filed 14 Aug 2020.